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Accepted 2 July 2014Treatment response criteria for cancer necessarily assign
thresholds limited by the sensitivity of the particular tech-
nique used for detecting residual disease burden. It is now
recognized that “complete remission” based on morpholog-
ical criteria alone is a highly heterogeneous state with
correspondingly diverse clinical outcomes and that higher
sensitivity methods for quantiﬁcation of malignant disease
remaining after initial treatment can better risk stratify pa-
tients based on their risk of subsequent clinical “relapse” and
death. In this issue of Biology of Blood and Marrow Trans-
plantation, Logan et al. report on the use of next generation
sequencing (NGS) technology for high-sensitivity assessment
of clonal lymphocyte immune receptor rearrangements to
detect and track residual acute lymphoblastic leukemia (ALL)
in patients undergoing allogeneic hematopoietic stem cell
transplantation (allo-SCT) [1].
Although multiple techniques are available for high-
sensitivity detection of measurable hematological malig-
nancy disease burden (reviewed in [2]), their integration
into standard response criteria and routine clinical practice
has so far been limited to those cancer types with a single
characteristic genetic aberration (for example, chronic
myeloid leukemia and acute promyelocytic leukemia) de-
tectable by standardized quantitative PCR testing (qPCR) or
rare disorders, such as pediatric ALL, typically treated only
at tertiary centers with a critical mass of pathologist
expertise, experience, and capacity to correctly interpret
more complex ﬂow cytometry data. Most diagnostic sub-
types of leukemia, however, do not have a single patho-
gnomonic genetic feature or cell surface phenotype to allow
a single universal test for the detection of minimal, or, moreDOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.04.018.
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http://dx.doi.org/10.1016/j.bbmt.2014.07.002properly, measurable residual disease (MRD) [3] to be
exclusively used. Although an individualized MRD qPCR
assay for each ALL patient can be designed using rearranged
lymphocyte immune receptor sequence as a target, as has
already been proven effective in clinical trials [4], this
approach has obvious cost, convenience, and logistical
challenges and has not yet been widely adopted.
The NGS approach used by Logan et al. [1] allows
personalized, highly sensitive minimal/measurable residual
disease tracking using a generic laboratory platformwithout
the need to design patient-speciﬁc reagents. The in-
vestigators demonstrate that when NGS-based MRD in ALL
patients was measured before conditioning for allo-SCT, a
threshold of 104 could identify an extremely higherisk
group (representing 32% of those who underwent trans-
plantation) with signiﬁcantly increased post-transplantation
relapse risk with a 12-month posteallo-SCT disease-free
survival of 0%. After allo-SCT, patients with any detectable
MRD (106) invariably experienced clinical relapse (on
average 3months later) and ultimately died, whereas none of
the patients consistently MRD negative after allo-SCT re-
lapsed, with the only fatalities in this group related to com-
plications of the transplantation itself. This NGS MRD
methodology was applicable to 93% of the patients who had
adequate sample for testing stored, with the majority having
more than 1 clonally rearranged sequence suitable for MRD
monitoring available.
It has been recently been demonstrated that this NGS
approach has at least the sensitivity of allele-speciﬁc qPCR
for MRD detection in ALL [5] and other B cell malignancies
[6] and it likely outperforms ﬂow cytometryebased MRD
assessment in B lymphoblastic leukemia [5,7]. Although the
NGS platform has proven capable of MRD detection in
lymphoid malignancies with clonally rearranged immune
receptor genes as targets, such as B-ALL [1,5-7], T-ALL [8],
chronic lymphocytic leukemia [9], multiple myeloma, and
mantle cell lymphoma [6], it remains to be seen if the
intrinsic error rate associated with NGS [10] will also allow
the adoption of this technology for MRD detection more
broadly; for example, to the myeloid malignancies [11]
where single nucleotide variants predominate [12]. Addi-
tionally, it should be noted that there is evidence in
both lymphoid [13] and myeloid [14] acute leukemias for
intrapatient heterogeneity with signiﬁcant disease oligo-
clonality possible within any 1 patient, such that the
M.G. Della Porta & E.P. Alessandrino / Biol Blood Marrow Transplant 20 (2014) 1259e12611260predominant clone at presentation may differ from the
clone ultimately responsible for clinical relapse; further
work will be needed to determine if this will be a signiﬁcant
factor requiring modiﬁcation of the bioinformatics strategy
employed in post allo-SCT monitoring.
The prognostic signiﬁcance of MRD in patients with
ALL undergoing SCT had previously been established [15]
and the use of MRD-guided therapy has already resulted in
remarkable outcomes in the treatment of children with ALL
[16]. The advance, therefore, represented by this NGS
approach is the ability to have a standardized, extremely
sensitive MRD platform available for most cases of ALL. This
should allow the truly “next generation” era of MRD to be
reached; the use of highly sensitive measurement of dis-
ease burden to routinely determine treatment efﬁcacy and
make evidence-based clinical decisions, in real-time, re-
garding the most appropriate next therapeutic intervention
for an individual patient. Risk stratiﬁcation based not on
historical, population-average correlates of the likely disease
biology and chemo-sensitivity of the predominant leukemic
clone before any treatment, but rather on the actual amount
of malignant disease a patient still has left requiring treat-
ment at key clinical decision points “moves the goal posts”
and will allow true personalization of therapy.
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Accepted 5 July 2014The only potentially curative treatment for patients with
myelodysplastic syndrome (MDS) is allogeneic hematopoietic
stem cell transplantation (allo-HSCT). However, the effec-
tiveness of this approach is limited by considerable morbidity
and mortality. The introduction of reduced-intensity condi-
tioning regimens has resulted in a signiﬁcant reduction in
transplantation-related mortality, leading to a rapidly
growing number of transplantations in elderly patients.
Despite these recent advances, the long-term survival
rate is currently about 30% [1]. In MDS patients receiving
reduced-intensity conditioning, disease relapse represents
the leading cause of transplantation failure, especially in
those with an advanced disease stage (ie, intermediate-2
and high International Prognostic Scoring System risk). The
